Login
$CLNN
$3.65 -$0.01 (0.27%) After hours

$CLNN 8-K SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition

Submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in October 2026 seeking accelerated approval for CNM-Au8® in amyotrophic lateral sclerosis (ALS)

20 Oct 2026 8-K: Entry into a Material Definitive Agreement

Intermediate-sized Expanded Access Protocol for CNM-Au8 in Amyotrophic Lateral Sclerosis (ALS)

19 Oct 2026 8-K: Other Events

NDA submission seeks accelerated approval of CNM-Au8 based on neurofilament light chain biomarker data and clinical outcomes

16 Sep 2026 8-K: Entry into a Material Definitive Agreement; Other Events

This Securities Purchase Agreement (this “Agreement”) is dated as of September 15, 2026, between Clene Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its success...

14 Aug 2026 8-K: Results of Operations and Financial Condition

Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026

10 Aug 2026 8-K: Regulation FD Disclosure; Other Events

Survival benefit is concentrated in participants with NfL biomarker response: CNM-Au8®-treated patients whose NfL declined or stabilized lived significantly longer than concurrently randomized controls

22 May 2026 8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation +1 more

1. Purpose. The purpose of this Amended 2020 Stock Plan (the “Plan”) is to enable Clene Inc., a Delaware corporation (the “Company”), to attract and retain the services of (i) selected employees, officers, and directors of the Company or...

14 May 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition

After successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8® under the accelerated approval pathway in the third quarter of 2026

05 May 2026 8-K: Entry into a Material Definitive Agreement; Other Events

Clene Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 1,000,000...

04 May 2026 8-K: Regulation FD Disclosure; Other Events

FDA stated that the “proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway” for CNM-Au8 based on neurofilament light (NfL) biomarker data

17 Mar 2026 8-K: Entry into a Material Definitive Agreement

Name: New York University, on behalf of its Grossman School of Medicine

12 Mar 2026 8-K: Results of Operations and Financial Condition

In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8® data submitted; Clene expects formal written meeting minutes early in the second quarter 2026

24 Feb 2026 8-K: Other Events

Operating capital runway sufficient into the fourth quarter of 2026

13 Jan 2026 8-K: Entry into a Material Definitive Agreement; Other Events

This Securities Purchase Agreement (this “Agreement”) is dated as of January 8, 2026, between Clene Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors...

12 Jan 2026 8-K: Other Events

The FDA has granted an in-person Type C meeting during the first quarter of 2026

03 Dec 2025 8-K: Regulation FD Disclosure

On December 3, 2025, Clene Inc. (the “Company”) hosted a conference call and webcast to provide an update on its CNM-Au8® program in amyotrophic lateral sclerosis (“ALS”). A copy of the presentation is furnished as Exhibit 99.1 to this C...

03 Dec 2025 8-K: Other Events

FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8

13 Nov 2025 8-K: Results of Operations and Financial Condition

As the U.S. Food and Drug Administration (FDA) proposed, Clene is concluding analyses of its ALS biomarker data with completion planned shortly

17 Oct 2025 8-K: Other Events

200 South Orange Avenue, Suite 2600 | Orlando, FL 32801 | T 407.425.8500 | F 407.244.5288

14 Oct 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

On October 14, 2025, Clene Inc. (“the Company”) released an updated corporate presentation (the “Corporate Presentation”) on its website, invest.clene.com, containing the Company’s preliminary unaudited (i) balance of cash and cash equiv...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support